Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 533 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Particle Clear all
Completed Not applicable Interventional

A Defined, Plant-based, 4-week Dietary Intervention Reduces Lp(a) and Other Atherogenic Particles

NCT03172611
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Dietary Intervention
Other
Lead sponsor
Texas Woman's University
Other
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 23, 2026, 10:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA

NCT01147965
View directory record Official record
Conditions
Colorectal Cancer, Lung Cancer, Breast Cancer, Prostate Cancer
Interventions
Ad5 CEA Vaccine
Biological
Lead sponsor
NantCell, Inc.
Industry
Eligibility
21 Years to 75 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
2
States / cities
Durham, North Carolina • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 23, 2026, 10:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Determine How Long Insulin and FDKP (the Molecule That Forms Technosphere Particles) Stays in the Lungs of Healthy Individuals After Inhalation of Technosphere® Insulin (TI) Powder Using Bronchoalveolar Lavage (BAL)

NCT00757367
View directory record Official record
Conditions
Healthy Subjects
Interventions
TI Inhalation Powder
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 45 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Oct 23, 2026, 10:14 PM EDT
Completed Phase 2 Interventional Results available

A Study of Accelerated 3 Fraction Photon,Proton or Brachytherapy for Early Invasive and Noninvasive Breast Ca

NCT02453737
View directory record Official record
Conditions
Breast Cancer
Interventions
Brachytherapy APBI, 3D-CRT (photon) APBI, Proton APBI
Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years and older · Female only
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 23, 2026, 10:14 PM EDT
Recruiting Early Phase 1 Interventional

99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer

NCT04857502
View directory record Official record
Conditions
Prostate Carcinoma, Recurrent Prostate Carcinoma
Interventions
99mTc-based PSMA Imaging and Surgery Agent, Computed Tomography, Single Photon Emission Computed Tomography
Drug · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 23, 2026, 10:14 PM EDT
Not listed Not applicable Interventional

Prostate Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia

NCT02592473
View directory record Official record
Conditions
Prostatic Hyperplasia, Benign Prostatic Hyperplasia (BPH), Prostatism, Lower Urinary Tract Symptoms (LUTS), Prostatic Hypertrophy, Hyperplasia, Male Urogenital Diseases, Genital Diseases, Male
Interventions
Embozene Microspheres
Device
Lead sponsor
University of Virginia
Other
Eligibility
45 Years to 80 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 23, 2026, 10:14 PM EDT
Completed No phase listed Observational Results available

Change in Knowledge After Receiving Personal Air Pollution Results

NCT05160948
View directory record Official record
Conditions
Environmental Exposure
Interventions
Informational Report
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
15 Years to 99 Years
Enrollment
105 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 23, 2026, 10:14 PM EDT
Completed Not applicable Interventional Results available

Prostate Artery Embolization (PAE) for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

NCT02930889
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Prostate Artery Embolization
Device
Lead sponsor
University of Minnesota
Other
Eligibility
45 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Oct 23, 2026, 10:14 PM EDT
Active, not recruiting Phase 3 Interventional

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

NCT03801876
View directory record Official record
Conditions
Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Thoracic Esophagus Squamous Cell Carcinoma
Interventions
Biospecimen Collection, Capecitabine, Carboplatin, Computed Tomography, Docetaxel, Esophagectomy, Fluorouracil, Intensity-Modulated Radiation Therapy, Leucovorin Calcium, Oxaliplatin, Paclitaxel, Positron Emission Tomography, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Radiation + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2036
U.S. locations
96
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 77 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 23, 2026, 10:14 PM EDT
Completed Phase 1 Interventional Results available

NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine

NCT00199849
View directory record Official record
Conditions
Prostate Cancer, Bladder Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Sarcoma
Interventions
NY-ESO-1 Plasmid DNA Cancer Vaccine
Biological
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 23, 2026, 10:14 PM EDT
Completed Not applicable Interventional Results available

SPECT/CT in Measuring Lung Function in Patients With Cancer Undergoing Radiation Therapy

NCT01982123
View directory record Official record
Conditions
Lung Carcinoma, Malignant Neoplasm
Interventions
SPECT/CT, Single Photon Emission Computed Tomography, Technetium Tc-99m Albumin Aggregated, Technetium Tc-99m DTPA
Diagnostic Test · Procedure · Radiation + 1 more
Lead sponsor
University of Washington
Other
Eligibility
19 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 23, 2026, 10:14 PM EDT
Active, not recruiting Phase 1 Interventional

Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma

NCT05496686
View directory record Official record
Conditions
Uveal Melanoma, Metastatic
Interventions
4.7 microCi 225Ac-MTI-201, 9.5 microCi of 225Ac-MTI-201, 19 microCi of 225Ac-MTI-201, 38 microCi of 225Ac-MTI-201, 76 microCi of 225Ac-MTI-201, 152 microCi of 225Ac-MTI-201, 254 microCi of 225Ac-MTI-201, 424 microCi of 225Ac-MTI-201, 564 microCi of 225Ac-MTI-201, 750 microCi of 225Ac-MTI-201, 998 microCi of 225Ac-MTI-201, 1327 microCi of 225Ac-MTI-201
Drug
Lead sponsor
Modulation Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 23, 2026, 10:14 PM EDT
Active, not recruiting Not applicable Interventional

CTSN Embolic Protection Trial

NCT06027788
View directory record Official record
Conditions
Delirium, Ischemic Stroke, Acute Kidney Injury, Heart Valve Disease, Coronary Artery Disease
Interventions
CardioGard Embolic Protection Cannula, Standard Aortic Cannula
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
60 Years and older
Enrollment
842 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
20
States / cities
North Little Rock, Arkansas • Los Angeles, California • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 23, 2026, 10:14 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer

NCT02423902
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Ad-RTS-hIL-12, Veledimex
Biological · Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 23, 2026, 10:14 PM EDT
Recruiting No phase listed Observational

SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism

NCT03222375
View directory record Official record
Conditions
Autistic Disorder, Autism Spectrum Disorder, Child Development Disorders, Pervasive, Neurodevelopmental Disorders, Mental Disorders, Asperger's Syndrome, Neurobehavioral Manifestations, Nervous System Diseases
Interventions
SQUED™ series 28.1 home-use
Device
Lead sponsor
American Federation of Medical Synergetics
Other
Eligibility
1 Month to 21 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Oct 23, 2026, 10:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Prolonged Fasting on Microbiome and HDL

NCT03487679
View directory record Official record
Conditions
Fasting
Interventions
Fasting
Other
Lead sponsor
University of California, Davis
Other
Eligibility
20 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Oct 23, 2026, 10:14 PM EDT
Recruiting Phase 2 Interventional

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

NCT04671667
View directory record Official record
Conditions
Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma
Interventions
Carboplatin, Cisplatin, Computed Tomography, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Pembrolizumab, Proton Beam Radiation Therapy
Drug · Procedure · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 79 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
178
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 128 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 23, 2026, 10:14 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Norovirus Bivalent-Vaccine Efficacy Study

NCT01609257
View directory record Official record
Conditions
Prevention From Norovirus Infection
Interventions
Norovirus Bivalent Vaccine, Saline Comparator
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 49 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
5
States / cities
Atlanta, Georgia • Baltimore, Maryland • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 23, 2026, 10:14 PM EDT
Terminated Phase 2 Interventional Results available

Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma

NCT04006119
View directory record Official record
Conditions
Glioblastoma
Interventions
Ad-RTS-hIL-12, Veledimex, Cemiplimab-Rwlc
Biological · Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 23, 2026, 10:14 PM EDT
Recruiting Phase 2 Interventional

Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

NCT06288113
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, Positron Emission Tomography, Questionnaire Administration, Single Photon Emission Computed Tomography
Procedure · Other · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 23, 2026, 10:14 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

NCT02543268
View directory record Official record
Conditions
Healthy
Interventions
Ad26.ZEBOV-Batch #1, Ad26.ZEBOV-Batch #2, Ad26.ZEBOV-Batch #3, MVA-BN-Filo, Placebo
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 50 Years
Enrollment
329 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
6
States / cities
Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 23, 2026, 10:14 PM EDT
Completed Not applicable Interventional

Preliminary Safety and Effectiveness of SMI-01 as a Tissue Filler

NCT04534660
View directory record Official record
Conditions
Nasolabial Fold, Cheek Augmentation
Interventions
SMI-01
Device
Lead sponsor
Sofregen Medical, Inc.
Industry
Eligibility
22 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Encinitas, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Oct 23, 2026, 10:14 PM EDT
Not yet recruiting Not applicable Interventional

Comparative Study of Embolic Agents in Patients With Subdural Hemorrhage Undergoing Middle Meningeal Artery (MMA) Embolization

NCT07757113
View directory record Official record
Conditions
Chronic Subdural Hematoma, Stroke, Middle Meningeal Artery Embolization
Interventions
Particles (polyvinyl alcohol or similar microspheres), Liquid Embolics (Onyx, n-BCA, or equivalent), Phenox Coils (Avenir UNO Helical Coil)
Device
Lead sponsor
Sanford Health
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 23, 2026, 10:14 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Impact of a Known Bioactive Agent on the Resolution of Alveolar Socket Preservation

NCT02802436
View directory record Official record
Conditions
Healing of Extraction Socket
Interventions
Extraction with socket graft
Procedure
Lead sponsor
Boston University
Other
Eligibility
20 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 23, 2026, 10:14 PM EDT